Bailitianheng iza-bren (EGFR×HER3 dual anti-ADC) was recognized as the 6th breakthrough treatment for CDE, and is used for platinum-resistant recurrent ovarian cancer, etc.Recently, Baili Tianheng's innovative drug iza-bren (EGFR×HER3 dual anti-ADC) was awarded the 6th breakthrough treatment certi

CDE solicits opinions on the "Detailed Rules for Application and Management of Class I Conferences in Advanced Therapeutic Drug Communication", aiming to accelerate the review of cell and gene therapy drugsRecently, the Drug Review Center (CDE) of the State Drug Administration issued the "Detailed R